Riding the Waves of New Small Cell Lung Cancer Therapeutics

This activity discusses current evidence for radiotherapy in the management of SCLC. New phase III data combining radiation and immunotherapy (Adriatic, LU-005) is presented, with particular attention on the importance of timing of immunotherapy relative to chemoradiation. Nuances in the timing of radiation, commonly delivered dose fractionations, and new data on the relative benefits of dose escalation, whether with once a day or twice a day treatment are discussed. The relative merits and risks of consolidative thoracic radiation and stereotactic radiotherapy in extensive stage SCLC are explored. Novel systemic options with T-cell engagers, antibody drug conjugates (ADCs) are discussed in the context of extensive stage SCLC in the context of future combinations with consolidative radiation therapy. Finally, case-based scenarios highlighting pertinent clinical pearls of the above scenarios are presented, with discussion among all speakers.

Topics:

  1. Immunotherapy in Limited Stage Small Cell Lung Cancer: Dissecting the Data
    Kristin Higgins, MD
  2. Extensive Stage SCLC: Role for Consolidative Radiation Therapy?
    Quynh-Nhu Nguyen, MD, FASTRO, MHCM
  3. Emerging Novel Systemic Treatment Options in Extensive Stage SCLC
    Stephen V. Liu, MD
  4. Case Based Discussion/Q and A
    Percy Lee, MD - Moderator
    Full Panel

This activity is available from August 11, 2026, through 11:59 p.m. Eastern time on August 10, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, radiation biologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the evidence for optimal dose fractionations, timing of radiotherapy and immunotherapy for limited stage SCLC. 
  • Identify and discuss the controversies on the use of thoracic radiotherapy in extensive stage SCLC.
  • Review emerging systemic options such as T-cell engagers, antibody drug conjugates (ADCs) for extensive stage SCLC. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
08/11/2026
Course expires: 
08/10/2028
Cost:
$149.00
Rating: 
0

Moderator:  

  • Percy Lee, MD, FASTRO, is employed by City of Hope. Dr. Lee receives grant/research funding from AstraZeneca, Inc. and ViewRay, Inc. Dr. Lee receives honoraria from AstraZeneca, Inc., Genentech, Inc., Johnson & Johnson, Roche, RTOG Foundation, Varian, Inc. and ViewRay, Inc. 

Speakers:

  • Kristin Higgins, MD, is employed by City of Hope Atlanta. Dr. Higgins receives compensation/payment and/or salary support from Janssen Pharmaceuticals, Jazz Pharmaceuticals and RefleXion Medical. Dr. Higgins receives honoraria from AstraZeneca and Genentech. Dr. Higgins owns stock options with Picture Health.
  • Quynh-Nhu Nguyen, MD, FASTRO, MHCM, is employed by The University of Texas MD Anderson Cancer Center. Dr. Nguyen has no relevant financial relationship with ineligible companies to disclose. 
  • Steven V. Liu, MD, is employed by Lombardi Comprehensive Cancer Center, Georgetown University. Dr. Liu receives compensation/payment from Jazz Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, F. Hoffmann-LaRoche AG, Johnson & Johnson, Abbvie, Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Takeda, Yuhan, Guardant Health, GSK, Gilead, SystImmune, Immunotherapeutics, Novartis, Merus, Natera, Pfizer, Regeneron and Revolution Med. Dr. Liu receives grant/research funding from AstraZeneca Pharmaceuticals LP, Nuvation, Puma, F. Hoffmann-LaRoche AG, Abbvie, Amgen, Merck, Nuvalent, Medilink, Gilead, SystImmune, OSE, Merus, Duality, Cogent Biosciences, BioNTech, Alkermes, Ellipses and Synthekine.   

Planners:

  • Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 
     

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until August 10, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.